MA32230B1 - Formes cristallines et deux formes solvatées de lactates de 4-amino-5-fluoro -3-[5-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one - Google Patents

Formes cristallines et deux formes solvatées de lactates de 4-amino-5-fluoro -3-[5-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one

Info

Publication number
MA32230B1
MA32230B1 MA33250A MA33250A MA32230B1 MA 32230 B1 MA32230 B1 MA 32230B1 MA 33250 A MA33250 A MA 33250A MA 33250 A MA33250 A MA 33250A MA 32230 B1 MA32230 B1 MA 32230B1
Authority
MA
Morocco
Prior art keywords
forms
amino
methylpiperazine
benzimidazole
quinoline
Prior art date
Application number
MA33250A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Danielle Giron
Walter Hammerschmidt
Philippe Piechon
Johanne Polasek
Andreas Schreiner
Frank Stowasser
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40622140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32230(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA32230B1 publication Critical patent/MA32230B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA33250A 2008-03-19 2010-10-15 Formes cristallines et deux formes solvatées de lactates de 4-amino-5-fluoro -3-[5-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one MA32230B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3774608P 2008-03-19 2008-03-19
PCT/EP2009/053222 WO2009115562A2 (en) 2008-03-19 2009-03-18 Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts

Publications (1)

Publication Number Publication Date
MA32230B1 true MA32230B1 (fr) 2011-04-01

Family

ID=40622140

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33250A MA32230B1 (fr) 2008-03-19 2010-10-15 Formes cristallines et deux formes solvatées de lactates de 4-amino-5-fluoro -3-[5-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one

Country Status (24)

Country Link
US (1) US8563556B2 (enExample)
EP (1) EP2257544B1 (enExample)
JP (1) JP2011515370A (enExample)
KR (1) KR20100137517A (enExample)
CN (1) CN101970425B (enExample)
AR (1) AR070924A1 (enExample)
AU (1) AU2009227003B2 (enExample)
BR (1) BRPI0909762A2 (enExample)
CA (1) CA2718076A1 (enExample)
CL (1) CL2009000651A1 (enExample)
CO (1) CO6321253A2 (enExample)
EC (1) ECSP10010555A (enExample)
IL (1) IL208020A0 (enExample)
MA (1) MA32230B1 (enExample)
MX (1) MX2010010152A (enExample)
MY (1) MY150554A (enExample)
NZ (2) NZ600887A (enExample)
PE (1) PE20091628A1 (enExample)
PH (2) PH12012502569A1 (enExample)
RU (1) RU2497820C2 (enExample)
SG (1) SG188919A1 (enExample)
TW (1) TWI426072B (enExample)
WO (1) WO2009115562A2 (enExample)
ZA (1) ZA201006263B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR070924A1 (es) 2008-03-19 2010-05-12 Novartis Ag Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona
WO2011128405A1 (en) 2010-04-16 2011-10-20 Novartis Ag Combination of organic compounds
PL2558095T3 (pl) 2010-04-16 2019-06-28 Novartis Ag Związek organiczny, przeznaczony do stosowania w leczeniu raka wątroby
AR081776A1 (es) 2010-06-30 2012-10-17 Novartis Ag Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, proceso para la produccion de la composicion
AU2012229107A1 (en) 2011-03-17 2013-09-19 Novartis Ag FGFR and ligands thereof as biomarkers for breast cancer in HR positive subjects
MX2013013437A (es) 2011-05-19 2013-12-06 Novartis Ag 4-amino-5-fluoro-3- [6- (4-metil-piperazin-1-il) -1h-bencimidazol-2-il] -1h-quinolin-2-ona parea usarse en el tratamiento de un carcinoma adenoide quistico.
KR20140062485A (ko) 2011-09-15 2014-05-23 노파르티스 아게 중등도 간 손상 환자의 암 치료에 있어서 4-아미노-5-플루오로-3-[6-(4-메틸피페라진-1-일)-1h-벤즈이미다졸-2-일]-1h-퀴놀린-2-온의 용도
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
JP2015505562A (ja) 2012-01-31 2015-02-23 ノバルティス アーゲー Ｒｔｋ阻害剤と抗エストロゲン剤との組合せ、およびがん治療のためのその使用
BR112015000349A2 (pt) 2012-07-11 2017-06-27 Novartis Ag método de tratamento de tumores estromais gastrointestinais
WO2014058785A1 (en) 2012-10-10 2014-04-17 Novartis Ag Combination therapy
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
LT3116909T (lt) 2014-03-14 2020-02-10 Novartis Ag Antikūno molekulės prieš lag-3 ir jų panaudojimas
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP3206711B1 (en) 2014-10-14 2023-05-31 Novartis AG Antibody molecules to pd-l1 and uses thereof
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
PE20171448A1 (es) 2015-03-10 2017-10-02 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion dependiente del estimulador del gen de interferon
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
CN114272371A (zh) 2015-07-29 2022-04-05 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
EP3317301B1 (en) 2015-07-29 2021-04-07 Novartis AG Combination therapies comprising antibody molecules to lag-3
CA3004138A1 (en) 2015-11-03 2017-05-11 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and tim-3 and their uses
ES2986067T3 (es) 2015-12-17 2024-11-08 Novartis Ag Moléculas de anticuerpos frente a PD-1 y usos de las mismas
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE309996T1 (de) * 2000-09-11 2005-12-15 Chiron Corp Chinolinonderivate als tyrosin-kinase inhibitoren
US20050256157A1 (en) * 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
EP1539754A4 (en) * 2002-08-23 2009-02-25 Novartis Vaccines & Diagnostic BENZIMIDAZOCHINOLINONE AND ITS USE
US7825132B2 (en) * 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
US7838527B2 (en) * 2002-11-13 2010-11-23 Novartis Vaccines And Diagnostics, Inc. Methods of treating cancer and related methods
CN100377709C (zh) * 2002-11-13 2008-04-02 希龙公司 受体酪氨酸激酶抑制剂的制药用途及相关检测方法
JP4890255B2 (ja) * 2003-11-07 2012-03-07 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 改良された薬物特性を有するキノリノン化合物の薬学的に受容可能な塩
RU2377988C2 (ru) * 2004-02-20 2010-01-10 Новартис Вэксинес Энд Дайэгностикс, Инк. Модуляция воспалительных и метастатических процессов
SG173317A1 (en) * 2005-01-27 2011-08-29 Novartis Vaccines & Diagnostic Treatment of metastasized tumors
AU2006249847B2 (en) * 2005-05-23 2012-12-20 Novartis Ag Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
NZ567550A (en) 2005-11-29 2011-08-26 Novartis Ag Formulations of lactic acid salts of 4-amino-5-fluoro-3-[6-(4-methyl-piperazin-1-yl)-1 H-benzimidazol-2-yl]1H-quinolin-2-one
AR070924A1 (es) 2008-03-19 2010-05-12 Novartis Ag Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme

Also Published As

Publication number Publication date
AR070924A1 (es) 2010-05-12
US8563556B2 (en) 2013-10-22
EP2257544A2 (en) 2010-12-08
ZA201006263B (en) 2011-05-25
RU2010142396A (ru) 2012-04-27
CN101970425B (zh) 2014-04-16
RU2497820C2 (ru) 2013-11-10
WO2009115562A2 (en) 2009-09-24
CL2009000651A1 (es) 2010-07-19
IL208020A0 (en) 2010-12-30
PH12012502568A1 (en) 2014-10-27
AU2009227003B2 (en) 2013-03-14
AU2009227003A1 (en) 2009-09-24
HK1147492A1 (en) 2011-08-12
CN101970425A (zh) 2011-02-09
KR20100137517A (ko) 2010-12-30
TWI426072B (zh) 2014-02-11
CO6321253A2 (es) 2011-09-20
MX2010010152A (es) 2010-10-25
BRPI0909762A2 (pt) 2018-04-03
ECSP10010555A (es) 2010-11-30
PH12012502569A1 (en) 2015-09-21
WO2009115562A3 (en) 2009-11-26
EP2257544B1 (en) 2014-12-03
CA2718076A1 (en) 2009-09-24
JP2011515370A (ja) 2011-05-19
US20110021536A1 (en) 2011-01-27
TW201000463A (en) 2010-01-01
SG188919A1 (en) 2013-04-30
NZ587829A (en) 2012-08-31
NZ600887A (en) 2013-10-25
MY150554A (en) 2014-01-30
PE20091628A1 (es) 2009-11-19

Similar Documents

Publication Publication Date Title
MA32230B1 (fr) Formes cristallines et deux formes solvatées de lactates de 4-amino-5-fluoro -3-[5-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one
MA43116A (fr) Ditosylate de valbénazine et polymorphes associés
MA32226B1 (fr) Compositions et leurs procedes de preparation et d'utilisation
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
TN2011000626A1 (en) 1h-imidazo[4,5-c]quinolinone derivatives
MA34765B1 (fr) Antagonistes des récepteurs de l'acide lysophosphatidique et utilisations de ceux-ci
EA201100032A1 (ru) Соединения пиридина
MA34169B1 (fr) Dérivés d'acide 1-amino-2-cyclopropyléthylboronique
MA29532B1 (fr) Formes cristallines et autres de sels d'acide lactique 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one
MA37742B1 (fr) Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments
MA31952B1 (fr) Pyrrolopyrimidines et pyrrolopyridines
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
MY143795A (en) Tetrahydropyridoindole derivatives
MY147677A (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
MA33679B1 (fr) Derives de 2-oxo-1-pyrrolidinyle imidazothiadiazole
ATE487720T1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
WO2011151722A3 (en) Methods and compositions for oral pharmaceutical therapy
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
MA30554B1 (fr) Malates et formes polymorphes de l'acide ( 3s,5s)-7-[3-amino-5-methyl-piperidinyl ]-1-cyclopropyl-1,4-dihydro-8- methoxy-4-oxo-3-quinoleine-carboxylique
MA32224B1 (fr) Derives de (pyrazolyl-carbonyl) imidazolidinone pour le traitement de maladies retrovirales
EP2134712A4 (en) ASPARTATE FROM 1-CYCLOPROPYL-6-FLUOR-7- (8-METHOXYIMINO-2,6-DIAZA-SPIRO [3.4] OCT-6-YL) -4-OXO-1,4-DIHYDRO- [1,8] NAPHTHYRIDINE -3-CARBOXYLIC ACID, METHOD FOR THE PRODUCTION THEREOF AND ANTIMICROBIAL PHARMACEUTICAL COMPOSITION THEREWITH
MA37524B1 (fr) Procedes de production de chlorhydrate d'anamoreline presentant une teneur en chlorure regulee
MX2008001211A (es) Derivados de bencilpiperazina y su uso medico.
PH12014501051A1 (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
EP2583966A4 (en) TRICARBONYL TECHNETIUM 99M OR RHENIUM 188 MARKING RING RGD DERIVATIVE, METHOD OF PREPARING THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE DERIVATIVE AS AN ACTIVE INGREDIENT FOR USE IN THE DIAGNOSIS OR TREATMENT OF ANGIOGENIC ASSOCIATED DISEASES